Lee Hambright
Stock Analyst at Bernstein
(3.38)
# 978
Out of 5,131 analysts
34
Total ratings
75%
Success rate
10.4%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $97 → $99 | $93.34 | +6.07% | 2 | Jan 9, 2026 | |
| SYK Stryker | Maintains: Outperform | $450 → $465 | $369.62 | +25.80% | 4 | Jan 9, 2026 | |
| MDT Medtronic | Maintains: Outperform | $111 → $112 | $97.59 | +14.77% | 4 | Jan 9, 2026 | |
| JNJ Johnson & Johnson | Maintains: Market Perform | $193 → $208 | $204.74 | +1.59% | 6 | Jan 9, 2026 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $700 → $740 | $587.58 | +25.94% | 3 | Jan 9, 2026 | |
| DXCM DexCom | Maintains: Outperform | $84 → $86 | $66.78 | +28.78% | 3 | Jan 9, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $150 → $154 | $125.82 | +22.40% | 6 | Jan 9, 2026 | |
| PODD Insulet | Initiates: Outperform | $300 | $289.22 | +3.73% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $21.43 | +95.99% | 1 | Nov 6, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $97.47 | +2.60% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $85.27 | +58.32% | 3 | Mar 16, 2022 |
Zimmer Biomet Holdings
Jan 9, 2026
Maintains: Market Perform
Price Target: $97 → $99
Current: $93.34
Upside: +6.07%
Stryker
Jan 9, 2026
Maintains: Outperform
Price Target: $450 → $465
Current: $369.62
Upside: +25.80%
Medtronic
Jan 9, 2026
Maintains: Outperform
Price Target: $111 → $112
Current: $97.59
Upside: +14.77%
Johnson & Johnson
Jan 9, 2026
Maintains: Market Perform
Price Target: $193 → $208
Current: $204.74
Upside: +1.59%
Intuitive Surgical
Jan 9, 2026
Maintains: Outperform
Price Target: $700 → $740
Current: $587.58
Upside: +25.94%
DexCom
Jan 9, 2026
Maintains: Outperform
Price Target: $84 → $86
Current: $66.78
Upside: +28.78%
Abbott Laboratories
Jan 9, 2026
Maintains: Outperform
Price Target: $150 → $154
Current: $125.82
Upside: +22.40%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $289.22
Upside: +3.73%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $21.43
Upside: +95.99%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $97.47
Upside: +2.60%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $85.27
Upside: +58.32%